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Primary PCI has been consistently superior to thrombo-
lytic therapy within 3 h of onset of ST-segment elevation
myocardial infarction (STEMI). However, primary PCI is beset
with several problems. There is issue of lack of availability of
cath lab enabled centers with huge delays in transfers of
these patients to such centers. This issue is especially rele-
vant in developing countries with limited accessibility to
cath labs. Further, there is an issue of off-hours emergency
PCI which seems to have a worse outcome than daytime
procedures. Last but not the least, many physicians feel
rushed with need to do primary PCI and would love to get
some breathing space to consider other options, such as
CABG and medical therapy. Facilitated PCI (PCI after throm-
bolysis) was supposed to address several of these issues
particularly time delays with PCI but the results from several
trials were rather disappointing (particularly related to high
bleeding risks with this approach).1 On the other hand,
pharmacoinvasive PCI is a strategy wherein patients are
transferred to the major PCI center without the decision
being made for automatic immediate PCI on arrival.
TRANSFER AMI trial showed that this kind of therapy (dual
thrombolytic and PVI strategy) could be effective and bleed-
ing risks significantly reduced if PCI was performed at least
3 h after administration of thrombolysis.2
In the current article on the Strategic Reperfusion Early
after Myocardial Infarction (STREAM) study, Armstrong et al
describe a strategy of pre-hospital thrombolysis coupled with
coronary angiography and primary PCI in patients with STEMI
who presentedwithin 3 h after symptom onset andwho could
not undergo PCI within 1 h after the first medical contact.3
They demonstrate that this strategy is at least as effective as
that undertaking primary PCI on arrival to a cath lab enabled
center (without thrombolysis). When patients on tenecteplase
reached a major medical center, 36% needed urgent PCI
(decided by lack of ST resolution on ECG) and received it just
over 2 h after randomization. The other 64% of patients did not
need urgent PCI and received an angiogram in an average of
17 h after arrival and, based on the results, received PCI or
CABG under elective circumstances. This gave more time to
plan an elective procedure and also consider other options.
PCI at some point was performed in 90% of the PCI group vs.
80% of the thrombolysis group. CABG was performed in more
patients in the thrombolysis group (4.7% vs. 2.1%). The pri-
mary endpoint (a composite of all-cause mortality, shock,
congestive heart failure, and subsequent heart attack at 30days) occurred in 12.4% in the thrombolysis group vs. 14.3% in
the primary PCI group (relative risk in the thrombolysis group,
0.86; 95% confidence interval, 0.68e1.09; p ¼ 0.21). The end-
point reduction in the pharmacoinvasive group was driven
largely by heart failure and shock, and it also enabled more
patients to get bypass surgery, which might impact long-term
mortality. Another interesting finding was that patients with
inferiorMIs seemed to do better in the pharmacoinvasive arm,
which perhaps is reflective of the fact that lytic therapy is
more efficacious in recanalizing the right than the left coro-
nary artery. The only downside of pharmacoinvasive armwas
rate of intracranial bleeding in the thrombolysis group was
five times that in the primary PCI group (1.0% vs. 0.2%,
p ¼ 0.04). This fact was apparent early on the trial and led to a
reduction in the dose of tenecteplase in elderly. After that
amendment, which was made after 20% of planned recruit-
ment, these rates declined to (0.5% vs. 0.3%), respectively,
after the protocol amendment, with no difference in stroke
rates.
The conclusion of Armstrong and colleagues is con-
troversial, since there was a similar risk of the primary end
point in the two study groups and a significantly higher risk of
intracranial bleeding with early thrombolysis. Thus primary
PCI remains the treatment of choice in such patients who
have close access to cath lab centers. However, theremay be a
cost advantage with the avoidance of an urgent invasive
procedure in about two-thirds of these patients which may
offset the extra cost of the thrombolytic agent. Less shock and
heart failure in the thrombolysis group, coupled with the
promising long-term outcomes reported in studies of
pharmaco-invasive therapy reported previously certainly
indicates that pharmacoinvasive therapy may provide a use-
ful and reasonable option for many patients who cannot
undergo timely PCI. It is especially useful in situations where
PCI related delays such as occur in real-world situations, a
greater clinical benefit would be anticipated for early
pharmacoinvasive therapy. Major delays are prevalent in
remote and urban regions. Further, although primary PCI in
patients with STEMI is preferred, it is often unachievable.r e f e r e n c e s
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Objective: The purpose of the study was to investigate the
efficacy and safety of an intravenous ADP antagonist cangre-
lor, in the management of ischemic heart disease patients
going for PCI.
Background: Oral P2Y12 antagonist, clopidogrel has prob-
lems of slow onset of action and erratic absorption, difficulty
in administering to patients unable to swallow (intubated,
drowsy, sedated). Its long duration of action makes it more
prone to cause increased risk of bleeding, especially in emer-
gent CABG situations. Cangrelor, a new intravenous agent is
likely to be safer and efficacious in these respects.
Methods: The study was planned in 153 centers in 12
countries, randomizing 10,900 patients of Stable Angina, NSTE
ACS or STEMI, who were planned for PCI. Patients were
randomized in a double blind, double dummy manner.
Patients were randomized to either IV cangrelor or oral clo-
pidogrel 600 mg or 300 mg followed by maintenance dose
clopidogrel.
The primary efficacy endpoint (PEP) was death, myocardial
infarction (MI), Ischemia Driven Revascularization (IDR), and
stent thrombosis (ST) at 48 h as well as 30 days. The secondary
end points included individual components of the PEP as well
as stent thrombosis. Safety endpoint was GUSTO severe
bleeding at 48 h.
Results: The PEP was seen in 4.7% in cangrelor group while
5.9% in clopidogrel group OR 0.78 (0.66e0.93) p ¼ 0.005. Stent
thrombosis was 0.8% in cangrelor group while 1.4% in clopi-
dogrel group OR 0.62 (0.43e0.90) p ¼ 0.01. There was no dif-
ference in IDR, death or cardiac death. At 30 days, the benefits
of cangrelor persisted with PEP 0.85 (0.73e0.99) p ¼ 0.03; and
ST 0.68 (0.50e0.92) p ¼ 0.01.
Therewas no significant increase in GUSTOmajor bleeding
with cangrelor OR 1.5 (0.53e4.22) p ¼ 0.44 NS.
Conclusion: Intravenously administered cangrelor reduced
primary efficacy end point of death, MI, IDR, ST in a variety of
CAD patients (Stable angina, NSTEMI ACS, STEMI) by 22% in
the background of PCI compared to clopidogrel loading. This
benefit persisted over 30 days follow up. The SEP of ST was
also reduced by 38%. There was no substantial increase in
GUSTO major bleeding.1. Clinical perspective
Most new antiplatelets improve ischemic outcome at the cost
of increased bleeding. Also oral agents have a slow onset ofaction despite loading dose. Oral loading becomes a problem
when the patient is intubated, drowsy, or in shock and is
unable to take orally. The slow onset exposes the patient to a
higher ischemic event risk during PCI. Most oral agents have a
long half-life and a slow dissociation leading to increased
bleeding risk especially when considering a patient needing
emergent CABG.
Cangrelor an intravenous ADP antagonist with a short half-
life has a theoretical advantage of ‘quick inequick out’ met-
abolic profile. In this trial cangrelor showed efficacy better
than clopidogrel (PEP reduced by 22%) and stent thrombosis
reduced by 38%, the benefits persisting at 30 days follow up. At
the same time no increase in GUSTO major bleed was noted.
In this regard cangrelor joins the elite band of bivalirudin,
fondaparinux and ticagrelor which improve ischemic out-
come without compromising on safety.
Administration of cangrelor in the background of new
antiplatelets including prasugrel and ticagrelor (as loading) is
unknown. Also post cangrelor loading, which antiplatelet
would work the best as a maintenance agent is yet to be
decided. This trial confirms the hypothesis that a short acting
intravenous antiplatelet agent is safe and efficacious in the
most crucial first 48 h, persisting upto 30 days.
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M. Packer, W. Colucci, L. Fisher, et al.for the REVIVE Heart
Failure StudyGroup, Effect of levosimendanon the short-term
clinical course of patients with acutely decompensated heart
failure. J Am Coll Cardiol HF 1 (2013) 103e111.Objectives: The purpose of this study was to evaluate the
efficacy and safety of levosimendan, given intravenously to
patients with acutely decompensated heart failure (ADHF).
Background: Levosimendan, a positive inotropic drug with
vasodilator effects has been reported to produce favorable
effects on cardiac performance, symptoms, hospital stays and
survival in patients with ADHF. The hemodynamic effects of
levosimendan persist for many days after a 24 h infusion, due
to a long-lived active metabolite. However, it is not clear that
these hemodynamic effects translate into clinical benefits and
improved outcomes.
Methods: Two sequential trials were performed, the first to
develop a new measure of efficacy in 100 patients, and the
second to use this measure to evaluate levosimendan in an
additional 600 patients. Patients admitted with ADHF received
placebo or intravenous infusion of levosimendan for 24 h in
addition to standard treatment. The primary endpoint was a
composite that evaluated changes in clinical status during the
first 5 days after randomization.
Results: In the 600-patient trial, more levosimendan than
placebo patients improved at all 3 pre-specified time points
(6 h, 24 h, and 5 days), whereas fewer levosimendan
patients experienced clinical worsening (p ¼ 0.015). These
differences were apparent, despite more frequent
